NEW YORK – Veracyte on Tuesday announced preliminary fourth quarter revenue growth of 14 to 18 percent.
The firm has also entered a definitive agreement to acquire San Diego-based urologic cancer test developer Decipher Biosciences for $600 million in cash and stock.
Veracyte said that it expects Q4 revenue of $34.0 to $35.0 million compared to $29.7 million a year ago and above the consensus Wall Street estimate of $31.8 million. The firm expects Q4 product and testing volume of between 13,000 and 13,200 tests.